Birth control pills to combat obesity is about to agree

The next large obesity medicine is likely to come in the pipeline in the form of birth control pills. ELI Lilly just released the latest results of the third positive stage experience of the GLP-1 experimental mouth, Orforglipron.

On Tuesday morning, Elie Lily I mentioned This or for for-Grglipron fulfills the standards of studying the third phase of the company. The study showed that people who take OrforiPron suffered from significant improvements in weight loss and blood sugar control compared to those who take an imaginary drug. Armed with data from two successful experiences for the third stage, the company plans to apply for approval from the Food and Drug Administration, with a decision on the expected medicine next year.

The newest child on the block

ATANE-2 trial was conducted across 10 countries and included more than 1,600 people who suffer from obese or overweight with type 2 diabetes. They were randomly chosen from volunteers either to receive fake courses or one of three doses of Orforipron, which was taken once a day (as common with GLP-1 treatment, people gradually reached the maximum dose with passing the time). Participants were tracked for 72 weeks.

The study found that the people on or Ovurcelbron lost more weight and saw a greater decrease in blood sugar than people in the placebo.

Those who take more drugs have shown more improvement. Individuals who have the highest dose of, vaccine or an average of about 10 % of the essential body weight, for example, compared to the average weight loss by 2.5 % who were seen in those who take an imaginary drug. The performance of the drug was better at all secondary end points as well, including a greater percentage of people who lost at least 15 % of their weight (nearly a third of those who got the highest dose).

Orforglipron seems to be safe and endured like existing GLP-1 medications. Common negative events included diarrhea, vomiting and constipation (more common for those on the highest dose). About 10 % of the participants are on the highest dose of treatment stopping due to their negative events, compared to 5 % of these on the imaginary medicine.

These results follow similar results from the company’s experience -1 experience Absolute Earlier this month, which has tested the drug on people with weight gain or obese without type 2 diabetes (in general, people who do not have diabetes tend to lose weight from more GLP-1 treatment than diabetics). The company will now officially push forward with approval from the Food and Drug Administration and other organizational agencies.

“With this positive data on hand, we are moving urgently towards global organizational presentations to meet the needs of patients who are waiting,” He said Kenneth Kester, Executive Vice President of Laila and Layla Coldymtabolic Health, in a statement from the company.

Why will it not be OPorglipron for everyone

Currently, there is only one GLP-1 on the market: Novo Nordisk, an oral form of amazing Smaglutide drugs (the active ingredient in OzemPIC and Wegovy) that was approved to treat type 2 diabetes. Novo Nordesk has to request The FDA approval to issue a higher dose of smaglutide orally to treat obesity, which may reach later this year. However, Eli Lilly’s Orforglipron will be the first GLP-1 of the next generation to lose weight if approved.

Hibbet because this approval will be, or it is likely to excel or completely excel over its competitors for several reasons.

For beginners, the drug may not outperform the latest GLP-1 treatments there. At the best that appears in the medicine so far, the ACAIN-1 experience, people who take Orforipron on average 12.4 % of their basic weight, which is of a degree that is less than 14 % lower weight in similar experiences from the injection-injected Wegovy from Novo Nordisk and also under the typical results seen with Tirzepatide’s ELI Lilly, which is a dual GLP-1/GIP. The arrival of high school pills for the high dose of Novo Nordisk in late 2025 may take some consumer base for OrforiPron.

However, many potential users may prefer the comfort of daily birth control pills that exceeded subcutaneous injection, even if it is a little worse in the event.

Oral GLP-1 pill is likely to be easier to produce collectively than injections, which can prevent or reduce the risk of wide-ranging deficiency that regularly affected Dolutide and Terzopatid in the early years of approval. There may be some people in the past that does not respond to the current treatments who will benefit from an attempt or in favor of Groglipron instead.

With the exception of any unexpected complications, Orforglipron is on the right track to be the next new GLP-1. But it will certainly not be the last, and the competition is on The best obesity medicine It is likely to heat only in the coming years.